<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606732</url>
  </required_header>
  <id_info>
    <org_study_id>CV_SPP_COVID19</org_study_id>
    <nct_id>NCT04606732</nct_id>
  </id_info>
  <brief_title>CardioVascular Disease Progression and Prognosis in COVID-19</brief_title>
  <acronym>CVP-Covid19</acronym>
  <official_title>Cardiovascular Clinical Features and Cardiovascular Therapies in the Development, Progression and Outcome of Patients With SARS-Cov-2 Related Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CVP-COVID19 registry is both a retrospective and prospective study design in order to&#xD;
      identify predictors of cardiovascular disease progression and mortality for COVID-19. The&#xD;
      registry enrolls consecutive patients with positive microbiological tests for SARS-CoV-2&#xD;
      admitted to an academic hospital in northern Italy for worsening of COVID-19 symptoms. The&#xD;
      study does not test any new diagnostic or therapeutic approach. Patients are treated&#xD;
      according to good clinical practice. Patients characteristics, including medical history&#xD;
      (with particular attention to cardiovascular and pneumological risk factors), features of&#xD;
      physical examination, results laboratory and radiological tests and treatments (pre- and&#xD;
      in-hospital) are related with patient outcome. Logistic analysis (univariate, multivariate&#xD;
      and propensity) are performed in order to identify factors associated with disease&#xD;
      progression. Primary endpoint: mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators and Members of Steering Committee:&#xD;
&#xD;
      Raffaele Bugiardini (Università di Bologna, Italy) Stefano Nava (Università di Bologna,&#xD;
      Italy) Elisabetta Poluzzi (Università di Bologna, Italy) Maria Carla Re (Università di&#xD;
      Bologna, Italy)&#xD;
&#xD;
      Study Coordinator Edina Cenko (Università di Bologna, Italy)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All causes mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>All causes mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>All causes mortality</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Covid19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients admitted to an academic hospital in northern Italy for worsening of&#xD;
        COVID-19 symptoms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        hospitalization for COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        age &lt;18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Carla Re</last_name>
    <role>Study Director</role>
    <affiliation>DIMES, Università di Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivia Manfrini, MD</last_name>
    <phone>393355612175</phone>
    <email>olivia.manfrini@unibo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Carla Re</last_name>
      <phone>00390512143023</phone>
      <email>mariacarla.re@unibo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bologna</investigator_affiliation>
    <investigator_full_name>Olivia Manfrini</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Pneumonia, Viral</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Covid-12</keyword>
  <keyword>ACE receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

